Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients [Phase 4]
Phase 4 clinical trial update evaluating the efficacy and safety of recombinant human thrombopoietin (rhTPO) for chemotherapy-induced thromb…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating the combination of selinexor, venetoclax, and azacitidine in newly diagnosed acute myeloid leukemia …
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Use of Venetoclax , AML , Sohag , Egypt
A clinical trial evaluating venetoclax for acute myeloid leukemia at Sohag University in Egypt has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study of JNJ-67571244 in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 study of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in relapsed or refractory acute myeloid leukemia or acut…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant [Phase 1, Phase 2]
A Phase 1/2 trial evaluating daratumumab plus donor lymphocyte infusion in relapsed acute myeloid leukemia after stem cell transplantation w…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS [Phase 2]
Phase 2 trial evaluating BST-236 as a single-agent therapy in adults with relapsed or refractory acute myeloid leukemia or high-risk myelody…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial update for the IDH2 inhibitor AG-221 (enasidenib) in IDH2-mutated myelodysplastic syndrome; the study is active but n…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 trial of the IDH1 inhibitor ivosidenib (AG-120) in IDH1-mutated myelodysplastic syndromes (also listed for acute myeloid leukemia); …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS [Phase 1]
A Phase 1 study from Novartis evaluating PDR001 and MBG453 with decitabine in acute myeloid leukemia or high-risk myelodysplastic syndromes …
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy [Phase 1]
This Phase 1 trial evaluated the combination of the STAT inhibitor OPB-111077 with Decitabine and Venetoclax in patients with Acute Myeloid …
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients [Phase 2]
Phase 2 trial evaluating ASTX727 with donor lymphocyte infusions after allogeneic stem cell transplantation in very high risk myelodysplasti…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab [Phase 1]
Phase 1 study evaluating pembrolizumab to augment graft-versus-leukemia effect in patients with myelodysplastic syndromes and acute myeloid …
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy [Phase 1]
A Phase 1 clinical trial update for LY3214996 in patients with acute myeloid leukemia who are not candidates for standard therapy, with the …
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of XmAb18968 (CD3-CD38) in relapsed or refractory acute myeloid leukemia and T-cell lymphoblastic leukemia/lymphoma has been t…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML [Phase 2]
Clinical trial update on RVU120 for relapsed/refractory acute myeloid leukemia in a Phase 2 study. The trial is currently active but not rec…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML [Phase 1]
Phase 1 trial update evaluating Tagraxofusp-erzs in combination with gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 [Phase 1]
Phase 1 study evaluating the safety and preliminary efficacy of combining Gemtuzumab ozogamicin with Venetoclax in adults with relapsed or r…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
A clinical trial investigating malnutrition and sarcopenia in older adults with acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]
A Phase 1 trial evaluating interferon-gamma (IFN-γ) for relapsed myelodysplastic syndrome and acute myeloid leukemia after allogeneic stem c…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [EARLY_Phase 1]
A Phase 1 trial evaluating a combination of sirolimus, idarubicin, and cytarabine in adults with newly diagnosed acute myeloid leukemia has …
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia [Phase 1, Phase 2]
This clinical trial update reports completed Phase 1/2 results for MEN1703 (SEL24) in participants with Acute Myeloid Leukemia. Results were…
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
This clinical trial update summarizes the study of oral venetoclax in participants with acute myeloid leukemia, focusing on adverse events a…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating a three-drug combination of azacitidine, venetoclax, and trametinib for relapsed or refractory acute myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation [Phase 2]
Phase 2 trial evaluating tocilizumab to prevent graft-versus-host disease after cord blood transplantation has been completed.